What stage does Monograph Capital Partners invest at?

Monograph Capital Partners invests at the Seed, Series A, Series B stages.

What sectors does Monograph Capital Partners focus on?

Monograph Capital Partners focuses on Biotech, Healthtech, Medical Devices.

Where is Monograph Capital Partners located?

Monograph Capital Partners is headquartered in London, GB.

Does Monograph Capital Partners lead rounds?

Yes, Monograph Capital Partners leads investment rounds.

Monograph Capital Partners

Venture capitalActively deploying

London · Seed–Series B · 20 people tracked

Also known as MONOGRAPH CAPITAL ADVISORS (UK), LLP · MONOGRAPH CAPITAL ADVISORS, L.P.

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Monograph Capital invests in innovative life sciences companies with the goal of turning promising science into life-changing treatments for patients worldwide. The firm operates as a transatlantic team focused on sourcing leading scientific innovation and supporting company development across geographic boundaries. It combines differentiated deal sourcing, long-standing relationships with pharmaceutical companies, deep medical expertise, and seasoned operating experience to build strong companies and create value for both company partners and investors, ultimately aiming to improve patient health outcomes over time.

Invests inBiotech Healthtech Medical DevicesEuropeLondonNorth AmericaSan FranciscoSingaporeUnited KingdomUnited States

Source: firm website, verified Aug 11, 2026.

Stage

Seed–Series B

London, GB

Leads rounds

Leads

Instruments

Equity

Founded

2021

Last 12 months

2 investments

Private fund assets

$325.5M

VC funds

Tracked investments

Team · 20 people

from the firm's website & public directories

Charles Conn· Partner· United Statesin

Partner and co-founder of Monograph focused on tech-enabled services businesses. Former CEO of Oxford Sciences Innovation and founding CEO of Ticketmaster-Citysearch; chairs Patagonia and previously led the Rhodes Trust.

c•••@monograph.bioreveal

Fred Cohen· Partner and Chairman· San Francisco, California, United Statesin

Founder and Investment Committee member of Monograph, which he co-founded in 2021. Previously co-founded Vida Ventures and was Managing Partner at TPG Biotechnology, and earlier a professor at UCSF.

f•••@monograph.bioreveal

Tim Funnell· Partner· London, England, United Kingdomin

Partner and co-founder of Monograph. Previously co-founded MiroBio and built companies at Syncona, Third Rock Ventures and Oxford Sciences; began his career at Boston Consulting Group.

t•••@monograph.bioreveal

Matt McAviney· Partner· San Francisco

Partner in Monograph's San Francisco office focused on company formation and early-stage biopharma investing. Previously spent over 10 years at NEA and F-Prime Capital and has helped form 30+ biotech companies.

Mike LaGatta· Partner and COO· Fort Worth, Texas, United Statesin

Partner and Chief Operating Officer at Monograph. Previously General Counsel of TPG Holdings and Chief Tax Officer of TPG, with over 20 years of investment management experience.

Travis Murdoch· Partner

t•••@monograph.bioreveal

Bonnie van Wilgenburg· Principal

b•••@monograph.bioreveal

Freddie Dear· Principal (Portfolio)· Londonin

Principal at Monograph who was part of the founding team of portfolio company Ascend Advanced Therapies and sits on the board of Nocion Therapeutics. Previously an Investment Partner at Syncona and part of the Wellcome Trust investment team.

f•••@monograph.bioreveal

Jaideep Dudani· Principal (Portfolio)· San Francisco, California, United Statesin

Principal at Monograph and founding CEO of portfolio company Ouro Medicines. Previously part of the founding team of HI-Bio, worked at Relay Therapeutics, and was the first associate at Vida Ventures.

j•••@monograph.bioreveal

Melisa Guven· Principal· Londonin

Principal in Monograph's London office leading investments in therapeutics and pharmaceutical services. Board observer at Elevara Medicines, Maxion Therapeutics and Prolynx; previously an Engagement Manager at L.E.K. Consulting.

m•••@monograph.bioreveal

Brandi O'Donnell· Chief of Staff & Executive Assistant

Chief of Staff and Executive Assistant to Fred Cohen. Previously supported multiple senior leaders at TPG including Co-CEO Jon Winkelried and Senior Advisors. Earlier career at Santa Fe Film Festival, Doha Film Institute, and America's Cup before transitioning to private equity and venture capital.

Brandi O’Donnell· Chief of Staff & EAin

Chief of Staff and EA to Fred Cohen. Previously supported leaders at TPG including Co-CEO Jon Winkelried, with an earlier career spanning film festivals and events.

Daniel Schwarz· Chief Financial Officer· Fort Worthin

Chief Financial Officer of Monograph, based in Fort Worth, leading financial operations, fund administration and reporting. Previously CFO/COO at Bios Partners and Associate Director at Crestline Investors.

Jennifer Shah· Head of Capital Formation· United Statesin

Head of Capital Formation leading fundraising and investor relations. Previously led fundraising and IR at Silver Lake and was a Director of Capital Raising at SoftBank Investment Advisers.

Jeremias Reich· Associate· London

Associate in Monograph's London office supporting sourcing, diligence and portfolio work. Previously a Consultant in McKinsey's Life Sciences practice and a Biotech Investment Analyst at NB Capital; trained as a physician.

Kristina Nebel· US Operations Manager· San Franciscoin

US Operations Manager in Monograph's San Francisco office with extensive experience supporting biotech C-suite executives, including at Walking Fish Therapeutics, Frontier Medicines and CODA Biotherapeutics.

Michelle He· Associate· San Francisco

Secondee Associate in Monograph's San Francisco office supporting investment activities in life sciences. Previously an Investment Manager at Tin Alley Ventures and started her career at Goldman Sachs.

Oscar Molina· Associate· San Francisco

Associate in Monograph's San Francisco office supporting sourcing, diligence and portfolio work across life sciences. Previously a Fellow at Longitude Capital.

Ramone Kersey· UK Head of Operations· Londonin

UK Head of Operations in Monograph's London office, combining operational oversight with executive support. Previously supported senior leaders at UnitedHealth Group and worked as a communications specialist at McKinsey.

Charlie Zhou· Investor· Londonin

Investment Manager in Monograph's London office (listed as Advisor, in Portfolio) leading new investments and supporting portfolio companies. Founding member of Ouro Medicines and board director at RegASK; previously at Bain & Company and a practicing physician.

c•••@monograph.bioreveal

What they invest in

from 8 of 24 portfolio companies

Biotech ×7Medical Devices ×5Healthtech ×4AI & Machine Learning ×1Deep Tech ×1Digital Health ×1Enterprise Software ×1SaaS ×1

HQs:United States×6Germany×1United Kingdom×1

Investments · 24 tracked

founders shown can be your intro path

By year:2026 · 1 2025 · 1 2024 · 1 2023 · 14 dated

UroGen PharmaNASDAQ: URGNJul 2023

A US-headquartered biotech company developing innovative solutions for urothelial and specialty cancers using RTGel hydrogel technology (exited July 2025).

BiotechPrinceton, US

Stuart Holden, M.D.(Director)Jason Smith(Executive Officer)Arie Belldegrun, M.D.(Director)Dan Wildman(Director)Fred Cohen, M.D.(Director)Don Kim(Executive Officer)

Elevaraelevara.com✓ verified

Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.

BiotechHealthtechMedical DevicesLondon, GB

Emma Tinsley(Founder & former CEO (now Non-Executive Director))Mai-Britt Zocca(CEO)

Nocion Therapeuticsnociontx.comin 𝕏Dec 2025

Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.

BiotechHealthtechMedical DevicesWatertown, US

MATTHEW FRANKEL(Executive Officer)PETER COUROSSI(Executive Officer)RICHARD BATYCKY(Executive Officer, Director)JAMES ELLIS(Executive Officer)MEREDITH FISHER(Director)MICHAEL LIPP(Executive Officer)

Board seatFreddie Dear· per SEC Form D

Ollin Biosciences, Inc.May 2026

A clinical-stage biotechnology company focused on therapies for vision-threatening conditions including wet AMD and diabetic macular edema.

Austin, US

Board seatTravis Murdoch· per SEC Form D

Ascend

A gene-to-GMP contract development and manufacturing organization for advanced modalities and gene therapies.

Ascend Advanced Therapiesascend-adv.comin

Ascend is a gene-to-GMP development partner that helps life-science companies advance advanced therapy products from the research bench through clinical stages.

BiotechHealthtechMedical DevicesMunich, DE

Autobahn

A clinical-stage biotechnology company developing adjunctive therapies for depressive illnesses and bipolar depression.

Autobahn Therapeutics, Inc.autobahntx.cominJun 2024

Autobahn develops medicines for central nervous system (CNS) disorders by leveraging regenerative mechanisms of the human body.

BiotechDeep TechMedical DevicesSan Diego, US

Kevin Finney(Chairman, President and CEO)John Borkholder(Executive Officer)

BoardKristina Burow(Director)Thomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)

AviadoBio Websiteaviadobio.comin 𝕏

CV Therapeuticsgilead.comin 𝕏

Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

Lou Lange(Founder)

Hibiohibio.com

Human Immunology Biosciences

A precision immunology company co-incubated with Arch Venture Partners leveraging human genetics for autoimmune disorder treatments (exited May 2024).

Maxion Therapeutics

A UK-based preclinical biotechnology company developing antibody drugs against ion channels and GPCRs using proprietary KnotBody technology.

Maxion Therapeutics Websitemaxiontherapeutics.comin 𝕏

MiroBio

A therapeutics company developing checkpoint agonist antibodies for autoimmune disease treatment based on Oxford University research (exited August 2022).

Odaiaodaia.aiin

Ollin Bioollin.bio

Ouro Medicinesouromedicines.comin

Ouro Medicines is a company based in South San Francisco, California.

BiotechSouth San Francisco, US

Prolynx

A US-based biotechnology company developing ultra-long-acting medicines for obesity and metabolic diseases using half-life extension technology.

Prolynxincprolynxinc.comin 𝕏

RegASKregask.comin 𝕏

RegASK provides an AI-native regulatory intelligence platform that monitors regulatory changes across 160+ markets, orchestrates compliance workflows, and pairs automation with a community of regulatory experts for validation.

AI & Machine LearningEnterprise SoftwareSaaS

Sudo

A clinical-stage neuro-immunology company advancing TYK2 inhibitors for multiple sclerosis and psoriasis.

Sudo Biosudobio.com

Urogenurogen.comin 𝕏

Exits · 1

IPOs and acquisitions across the tracked portfolio

UroGen PharmaNASDAQ: URGN

Portfolio news

latest coverage across their companies

About — Nocion Therapeutics - Nocion Therapeutics

Nocion Therapeutics · nociontx.com · Mar 20, 2026

Frequently asked questions

What stage does Monograph Capital Partners invest at?: Monograph Capital Partners invests at the Seed, Series A, Series B stages.
What sectors does Monograph Capital Partners focus on?: Monograph Capital Partners focuses on Biotech, Healthtech, Medical Devices.
Where is Monograph Capital Partners located?: Monograph Capital Partners is headquartered in London, GB.
Does Monograph Capital Partners lead rounds?: Yes, Monograph Capital Partners leads investment rounds.

Images

Similar investors

Capricorn Venture Partners

Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.

$270K – $10.8M

Sofinnova Ventures

Sofinnova is an investment firm that partners with biotech companies from inception through growth, supporting drug development, the regulatory process, company building, and IPO.

$100K – $15M

Kaiser Permanente Ventures

Kaiser Permanente Ventures is the corporate venture capital arm investing in healthcare companies that address real needs and deliver value for patients, providers, healthcare delivery systems, and communities.

$2M – $5M

Foresite Capital

Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.

Korea Investment Partners

Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.

$973K – $50M